GOLDENWELL BIOTECH, INC. Operating Income Loss

Quick Answer

GOLDENWELL BIOTECH, INC. reported Operating Income Loss of -$123.1 thousand for the year ending 2024.

  • GOLDENWELL BIOTECH, INC. showed a decrease of -6.3% in Operating Income Loss from 2023 to 2024.
  • This data is from GOLDENWELL BIOTECH, INC.'s annual report (Form 10-K), filed with the SEC on May 15, 2025.
  • XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2021 to 2024), GOLDENWELL BIOTECH, INC.'s Operating Income Loss has declined by 4.1%.
  • Historical annual values: Fiscal year 2024: -$123.1 thousand | Fiscal year 2023: -$115.8 thousand | Fiscal year 2022: -$985.1 thousand | Fiscal year 2021: -$118.3 thousand.
  • Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: